Drug Profile
ICT 01
Alternative Names: ICT-01; ICT01 - ImCheck TherapeuticsLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator ImCheck Therapeutics
- Class Anti-infectives; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer; Squamous cell cancer
- Phase I/II Acute myeloid leukaemia; Haematological malignancies; Solid tumours
- Research Infections
Most Recent Events
- 09 Dec 2023 Phase-I/II clinical trials in Acute myeloid leukaemia (First-line therapy, Combination therapy, Late-stage disease) in USA, Belgium, France, Germany, Spain, United Kingdom (IV) (NCT04243499)
- 09 Dec 2023 Pharmacodynamics data from preclinical study in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 03 Nov 2023 Efficacy, pharmacodynamic and adverse events data from a phase I/II trial in Solid tumors released by ImCheck Therapeutics